Navigation Links
Interleukin Genetics Reports Fourth Quarter and Year End 2008 Financial Results
Date:3/9/2009

tion. The award was given for the paper, "Interleukin-1 genotype-selective inhibition of inflammatory mediators by a botanical: a nutrigenetics proof of concept," which was published in Nutrition: The International Journal of Applied and Basic Nutritional Sciences.
  • Enhanced Company Leadership. Throughout 2008, Interleukin Genetics, Inc. enhanced its management team with the addition of a new chief financial officer, vice president of marketing, senior business development executive, and staffed other critical positions in research and development, public relations, human resources, laboratory management and computer and information technology.
  • The Company reported revenues of $10.0 million and a net loss of $6.7 million, or $(0.21) per basic and diluted common share, for the year ended December 31, 2008, compared to revenues in 2007 of $9.7 million and a net loss of $6.2 million, or $(0.22) per basic and diluted common share. The revenue increase is primarily attributable to growth in consumer product revenue in combination with increased royalty and contract research revenue offset by a slight decrease in genetic testing revenue.

    Research and development expenses were $3.6 million for the year ended December 31, 2008 compared to $2.9 million for the year ended December 31, 2007. The increase is attributable to expenses relating to the Company's sponsored research agreement with Yonsei University, as well as additional expenses relating to our patent portfolio.

    Selling, general and administrative expenses were $7.0 million for the year ended December 31, 2008 compared to $6.4 million for the prior year. The increase is primarily attributable to increased promotional and advertising expenses, as well as increased expenses due to additional headcount.

    Fourth Quarter Results

    Revenue for the three months ended D
    '/>"/>

    SOURCE Interleukin Genetics, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Interleukin Genetics Announces Management and Board Appointments
    2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
    3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
    4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
    5. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
    6. Interleukin Genetics Retains Top Life Science Communications Firms
    7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
    8. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
    9. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
    10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
    11. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
    (Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
    (Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
    (Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
    Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
    ... Narcotic and Pain-Management Market ... ... American Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading marketer, ... China,Aoxing Pharmaceutical Company, Inc. (OTC Bulletin Board: CAXG) ("China,Aoxing"), a ...
    ... CryoPort, Inc. (OTC,Bulletin Board: CYRX) (http://www.CryoPort.com ... personal profile on MyWallst.net available at, http://www.wallst.net . ... on which investors can comment, and links to ... Mywallst.net at, http://my.wallst.net/profile.php?ID=19849 . Stay updated about ...
    ... In Vivo ... Imaging-, HOPKINTON, ... introduced Bioware(R) Ultra cell lines,a range of ultra bright light producing tumor ... are,10 to 100 times brighter than cell lines created using traditional methods,which ...
    Cached Biology Technology:American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 2American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 3American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 4CryoPort Creates Personal Wall on Wallst.net's Financial Social Community, my.wallst.net 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3
    (Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
    (Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
    (Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
    Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
    ... 2009) Brief but personal intervention reduces drinking among ... The University of Texas School of Public Health. Results ... issue of the Journal of Consulting and Clinical ... UT School of Public Health Dallas Regional Campus, led ...
    ... Jan. 30, 2009 Screening a chemical library of ... identified two new classes that can be used to ... many types of cancer and degenerative diseases. "The ... cellular pathway represents an important step in developing therapeutic ...
    ... An experiment to study the effects of naturally deposited ... key piece of the puzzle surrounding iron,s role in ... research, conducted by an international team led by Raymond ... Matthew Charette, a marine chemist at the Woods Hole ...
    Cached Biology News:Intervention method reduces binge drinking 2UT Southwestern researchers disrupt biochemical system involved in cancer, degenerative disease 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 3
    Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
    ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
    1 unit is sufficient for 1 caspase activity assay....
    Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
    Biology Products: